Targeted Treatments for Myasthenia Gravis in Children and Adolescents
Pediatric Drugs · 2024-11 · 26 (6) · 719-740
DOI: 10.1007/s40272-024-00649-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Drugs, online erschienen am 28.08.2024. Verfasst von Sithara Ramdas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, MDUK Neuromuscular Centre, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 147 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Myasthenia gravis (MG) is an antibody-mediated disorder of the neuromuscular junction affecting children and adults. MG is a treatable condition with most patients requiring immunosuppression for disease control and/or remission. Juvenile myasthenia gravis (JMG) is rare in comparison with adult-onset MG but given the same underlying pathophysiology, treatment strategies are similar to those in adults. Until recently, there were only a few randomised controlled trials (RCTs) for MG treatments in adults and none in children, and management strategies were primarily based on expert consensus. In addition, treatment options for refractory MG cases have been severely limited, resulting in poor long-term quality of life in such patients due to the significant disease burden. Recently, there have been several RCTs focussing on novel therapeutic strategies with potentially promising outcomes, suggesting a change in MG management over the coming years and access to more effective and faster-acting drugs for MG patients. This paper will review current and new MG treatments including efgartigimod, eculizumab, rozanolixizumab, ravulizumab, and zilucoplan, with a focus on juvenile myasthenia gravis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Paediatrics, MDUK Neuromuscular Centre, University of Oxford, Oxford, UK.
- Department of Paediatric Neurology, John Radcliffe Hospital, Oxford, UK.
- Neurology Unit, Hospital Dona Estefânia, Unidade Local de Saúde São José, Centro Clínico Académico de Lisboa, Lisbon, Portugal.
- Department of Paediatric Neurology, Evelina London Children's Hospital, Guy's & St. Thomas' Hospital NHS Foundation Trust, Children's Neurosciences Centre, F02-Becket House, Lambeth Palace Road, London, SE1 7EU, UK.
- Women and Children's Health, Faculty of Life Sciences and Medicine (FoLSM), King's College London, London, UK.
- Department of Paediatric Neurology, Evelina London Children's Hospital, Guy's & St. Thomas' Hospital NHS Foundation Trust, Children's Neurosciences Centre, F02-Becket House, Lambeth Palace Road, London, SE1 7EU, UK. Hei…
Zitieren
APA
Ramdas, S., Painho, T., Vanegas, M. I., Famili, D. T., Lim, M. J., & Jungbluth, H. (2024). Targeted Treatments for Myasthenia Gravis in Children and Adolescents. Pediatric Drugs, 26(6), 719-740. https://doi.org/10.1007/s40272-024-00649-3
Vancouver
Ramdas S, Painho T, Vanegas MI, Famili DT, Lim MJ, Jungbluth H. Targeted Treatments for Myasthenia Gravis in Children and Adolescents. Pediatric Drugs. 2024;26(6):719-740. doi:10.1007/s40272-024-00649-3
BibTeX
@article{Ramdas2024,
author = {Ramdas, Sithara and Painho, Teresa and Vanegas, Maria I and Famili, Dennis T and Lim, Ming J and Jungbluth, Heinz},
title = {Targeted Treatments for Myasthenia Gravis in Children and Adolescents},
journal = {Pediatric Drugs},
year = {2024},
volume = {26},
number = {6},
pages = {719--740},
doi = {10.1007/s40272-024-00649-3}
}
EUVIMED